To elucidate the impact of Mettl1 inhibition on the reprogramming of the immune tumour composition, we employed an analysis of immunomodulatory molecules, including cytokines and chemokines, as surrogate markers of the immune cells present in the tumour. Here, METTL1 is linked to neoplasm.